| Code | Description | Claims | Beneficiaries | Total Paid |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
20,572 |
18,367 |
$1.24M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
14,254 |
12,808 |
$944K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
5,750 |
5,595 |
$650K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
5,445 |
5,313 |
$418K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,368 |
1,309 |
$226K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,722 |
1,662 |
$129K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
373 |
369 |
$66K |
| G0378 |
Hospital observation service, per hour |
56 |
55 |
$54K |
| 80053 |
Comprehensive metabolic panel |
6,645 |
6,382 |
$54K |
| T1015 |
Clinic visit/encounter, all-inclusive |
1,265 |
372 |
$53K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
1,114 |
1,094 |
$42K |
| 87631 |
|
352 |
346 |
$42K |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,259 |
2,201 |
$34K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,023 |
986 |
$33K |
| 80061 |
Lipid panel |
2,208 |
2,175 |
$29K |
| 80050 |
General health panel |
574 |
558 |
$27K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
960 |
917 |
$27K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
137 |
132 |
$26K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
5,823 |
5,558 |
$24K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,219 |
1,186 |
$19K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,682 |
1,619 |
$18K |
| 0002A |
|
403 |
403 |
$17K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
515 |
507 |
$16K |
| 70450 |
Computed tomography, head or brain; without contrast material |
216 |
212 |
$16K |
| 0001A |
|
414 |
412 |
$15K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,441 |
1,364 |
$13K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
393 |
242 |
$13K |
| 85027 |
|
1,716 |
1,658 |
$12K |
| 83735 |
|
1,614 |
1,515 |
$11K |
| 71046 |
Radiologic examination, chest; 2 views |
713 |
699 |
$10K |
| 72141 |
|
39 |
39 |
$10K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
545 |
499 |
$10K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
1,047 |
976 |
$9K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
87 |
86 |
$9K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
110 |
110 |
$9K |
| 84703 |
|
817 |
794 |
$8K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
454 |
434 |
$7K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
972 |
954 |
$7K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
319 |
314 |
$7K |
| 84484 |
|
728 |
671 |
$6K |
| 80320 |
|
460 |
427 |
$5K |
| 82607 |
|
374 |
362 |
$5K |
| 80329 |
|
367 |
343 |
$5K |
| 71045 |
Radiologic examination, chest; single view |
702 |
662 |
$5K |
| 81001 |
|
1,720 |
1,657 |
$5K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
123 |
123 |
$5K |
| 82043 |
|
530 |
524 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
145 |
140 |
$4K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
286 |
250 |
$4K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
49 |
26 |
$4K |
| 83690 |
|
744 |
712 |
$3K |
| 82570 |
|
438 |
428 |
$3K |
| 85730 |
|
474 |
452 |
$3K |
| 85610 |
|
807 |
707 |
$3K |
| 84439 |
|
323 |
316 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
314 |
296 |
$3K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
20 |
17 |
$2K |
| 82728 |
|
197 |
196 |
$2K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
109 |
109 |
$2K |
| 86803 |
|
121 |
117 |
$2K |
| 73030 |
|
85 |
81 |
$2K |
| 83540 |
|
268 |
266 |
$2K |
| 83605 |
|
286 |
268 |
$2K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
71 |
71 |
$2K |
| 80076 |
|
194 |
192 |
$2K |
| 73610 |
|
92 |
88 |
$2K |
| 72110 |
|
75 |
74 |
$2K |
| 84450 |
|
231 |
218 |
$2K |
| 73630 |
|
143 |
136 |
$2K |
| 84460 |
|
207 |
195 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
4,711 |
4,367 |
$1K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
12 |
12 |
$1K |
| 83550 |
|
231 |
229 |
$1K |
| 87340 |
|
56 |
54 |
$804.96 |
| 85379 |
|
81 |
80 |
$804.52 |
| 82746 |
|
66 |
64 |
$788.28 |
| 81003 |
|
251 |
246 |
$777.89 |
| 84153 |
|
30 |
30 |
$743.58 |
| 85007 |
|
204 |
197 |
$725.09 |
| 73564 |
|
30 |
29 |
$661.47 |
| 0003A |
|
15 |
15 |
$652.40 |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
16 |
15 |
$647.11 |
| 84436 |
|
63 |
63 |
$586.90 |
| 85652 |
|
182 |
172 |
$558.33 |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
12 |
12 |
$519.14 |
| 82550 |
|
95 |
89 |
$494.02 |
| 88142 |
|
27 |
26 |
$471.68 |
| 84702 |
|
26 |
24 |
$462.04 |
| G0476 |
Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test |
13 |
13 |
$439.59 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
14 |
14 |
$419.07 |
| 73130 |
|
35 |
33 |
$403.15 |
| 87040 |
|
16 |
15 |
$362.18 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
44 |
38 |
$336.62 |
| 82150 |
|
75 |
72 |
$300.09 |
| 87430 |
|
46 |
44 |
$278.20 |
| 87081 |
|
47 |
45 |
$224.92 |
| 82248 |
|
30 |
26 |
$204.25 |
| 73110 |
|
18 |
18 |
$199.76 |
| 84550 |
|
34 |
32 |
$190.38 |
| 86141 |
|
18 |
17 |
$183.73 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
865 |
820 |
$147.86 |
| 82565 |
|
27 |
25 |
$147.22 |
| 90714 |
|
40 |
38 |
$126.00 |
| 84520 |
|
26 |
25 |
$124.88 |
| 86140 |
|
38 |
38 |
$114.27 |
| 86593 |
|
13 |
12 |
$79.61 |
| 93041 |
|
13 |
12 |
$49.30 |
| J2704 |
Injection, propofol, 10 mg |
193 |
169 |
$36.10 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
483 |
419 |
$34.68 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
232 |
207 |
$25.38 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
16 |
15 |
$3.40 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
45 |
42 |
$2.04 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
125 |
120 |
$0.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
18 |
15 |
$0.00 |
| 87280 |
|
13 |
13 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
26 |
26 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
23 |
22 |
$0.00 |